BioDelivery Sciences International
Founded Year
1997Stage
Acq - P2P | AcquiredValuation
$0000Revenue
$0000About BioDelivery Sciences International
BioDelivery Sciences (NASDAQ: BDSI) is a specialty pharmaceutical company that leverages its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.On March 23rd, 2022, BioDelivery Sciences International was acquired by Collegium Pharmaceutical.
BioDelivery Sciences International Headquarter Location
4131 ParkLake Avenue Suite 225
Raleigh, North Carolina, 27612,
United States
919-582-9050
BioDelivery Sciences International Patents
BioDelivery Sciences International has filed 51 patents.
The 3 most popular patent topics include:
- Morphinans
- Phenols
- Dosage forms
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
12/21/2012 | 2/27/2018 | Analgesics, Morphinans, Phenols, Acute pain, Opioid antagonists | Grant |
Application Date | 12/21/2012 |
---|---|
Grant Date | 2/27/2018 |
Title | |
Related Topics | Analgesics, Morphinans, Phenols, Acute pain, Opioid antagonists |
Status | Grant |
Latest BioDelivery Sciences International News
Jun 11, 2022
Post-hoc analysis of pooled data from pivotal trials (NCT03009019, NCT03006276) of a novel self-emulsifying oral celecoxib solution (Elyxyb; Biodelivery Sciences International, Stoughton, MA) show that it is safe and effective for acute treatment of migraine. This formulation of celecoxib reaches maximal dose (Tmax) at 42 minutes for potentially faster acute treatment of migraine. Pain freedom at 2 hours occurred in 34.4% of those who treated a migraine attack at onset with this formulation of celecoxib vs 24% with placebo (P=.0002; modified intent-to-treat analysis)....
BioDelivery Sciences International Web Traffic
BioDelivery Sciences International Rank
When was BioDelivery Sciences International founded?
BioDelivery Sciences International was founded in 1997.
Where is BioDelivery Sciences International's headquarters?
BioDelivery Sciences International's headquarters is located at 4131 ParkLake Avenue, Raleigh.
What is BioDelivery Sciences International's latest funding round?
BioDelivery Sciences International's latest funding round is Acq - P2P.
Who are the investors of BioDelivery Sciences International?
Investors of BioDelivery Sciences International include Collegium Pharmaceutical, Broadfin Capital and The Hopkins Capital Group.
Who are BioDelivery Sciences International's competitors?
Competitors of BioDelivery Sciences International include Armgo Pharma, Flexion Therapeutics, EyePoint Pharmaceuticals, Foamix Pharmaceuticals, Genocea Biosciences and 11 more.
You May Also Like

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
RegeneMed, Inc. is accelerating the development of safer, more effective drugs by providing integrated high throughput platforms incorporating engineered human tissue-based assays. RegeneMed possesses patented, proprietary, core technologies enabling the in vitro growth of engineered human tissues, including liver, GI tract, bone marrow and blood-brain barrier. These tissue-based in vitro model systems will accelerate drug development and aims to debottleneck ADME/Tox evaluation, the leading cause of drug failures facing the pharmaceutical industry, per the company.

Presage Biosciences is an oncology company that focuses on evaluating patient response to drugs in clinical trials. The company uses CIVO technology to deliver pharmacologically appropriate concentrations of multiple drugs to different regions of a tumor – while the tumor is still in the patient.
The company's core business is and remains the development and production of Active Pharmaceutical Ingredient and parenteral formulations in the the form of solution and Lyophilized injection, in areas like anesthialogy and oncology.
Optimata Ltd. is a privately-owned science-based interdisciplinary company engaged in biosimulation technology for optimizing drug treatment protocols. Optimata partners with pharmaceutical and biotechnology companies to develop effective new treatments for diseases by simulating disease processes. This aims to reduce time-to-market and development costs while improving the competitive profile of the newly developed drug.
NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.